BMRN Q3 2021 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$409M-14.3% YoY

Gross Profit

$305M74.7% margin

Operating Income

-$53M-13.0% margin

Net Income

-$36M-8.9% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

-18.5%

Cash Flow

Operating Cash Flow

$97M

Free Cash Flow

$77M

Stock-Based Comp.

$49M

Balance Sheet

Total Assets

$6.0B

Total Liabilities

$1.7B

Stockholders' Equity

$4.3B

Cash & Equivalents

$617M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$409M	$477M	-14.3%
Gross Profit	$305M	$288M	+6.0%
Operating Income	-$53M	-$56M	+4.9%
Net Income	-$36M	$785M	-104.7%

Revenue Segments

Product

$394M96%

Royalty And Other

$15M4%

Geographic Segments

UNITED STATES

$196M48%

Europe

$115M28%

Rest Of World

$58M14%

Latin America

$39M10%